Regulatory approval

Published by the Health Canada. Approved

PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer with lymph node positive and/or hormone receptor negative disease.

This is written in the approval document.

Citation

Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00081278.PDF. Revised August 2025. Accessed April 2026.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies